CO2023008676A2 - Compuestos polipéptidos modificados con lactama - Google Patents

Compuestos polipéptidos modificados con lactama

Info

Publication number
CO2023008676A2
CO2023008676A2 CONC2023/0008676A CO2023008676A CO2023008676A2 CO 2023008676 A2 CO2023008676 A2 CO 2023008676A2 CO 2023008676 A CO2023008676 A CO 2023008676A CO 2023008676 A2 CO2023008676 A2 CO 2023008676A2
Authority
CO
Colombia
Prior art keywords
modified polypeptide
polypeptide compounds
lactam
lactam modified
compounds
Prior art date
Application number
CONC2023/0008676A
Other languages
English (en)
Inventor
Haiying He
Shuhui Chen
Guoping Hu
Jian Li
Zhixiang Pan
Zhigan Jiang
Original Assignee
Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd filed Critical Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd
Publication of CO2023008676A2 publication Critical patent/CO2023008676A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Una clase de compuestos polipéptidos modificados con lactama y su uso en la preparación de un fármaco para el tratamiento de enfermedades relacionadas.
CONC2023/0008676A 2020-12-02 2023-06-30 Compuestos polipéptidos modificados con lactama CO2023008676A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202011402979 2020-12-02
CN202011409947 2020-12-02
CN202110432060 2021-04-21
CN202110587056 2021-05-27
PCT/CN2021/135180 WO2022117056A1 (zh) 2020-12-02 2021-12-02 含内酰胺修饰的多肽类化合物

Publications (1)

Publication Number Publication Date
CO2023008676A2 true CO2023008676A2 (es) 2023-09-29

Family

ID=81853827

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0008676A CO2023008676A2 (es) 2020-12-02 2023-06-30 Compuestos polipéptidos modificados con lactama

Country Status (11)

Country Link
US (1) US20240067702A1 (es)
EP (1) EP4257597A1 (es)
JP (1) JP2023552362A (es)
KR (1) KR20230116894A (es)
CN (1) CN116615222A (es)
AU (1) AU2021391241B2 (es)
BR (1) BR112023010891A2 (es)
CA (1) CA3200881A1 (es)
CO (1) CO2023008676A2 (es)
MX (1) MX2023006419A (es)
WO (1) WO2022117056A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2023193727A1 (zh) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN02304A (es) * 2012-05-03 2015-08-07 Zealand Pharma As
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AU2016382394B2 (en) * 2015-12-31 2019-07-04 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN110903355A (zh) * 2019-10-31 2020-03-24 成都圣诺生物制药有限公司 一种Tirzepatide的制备方法

Also Published As

Publication number Publication date
EP4257597A1 (en) 2023-10-11
CA3200881A1 (en) 2022-06-09
MX2023006419A (es) 2023-08-15
WO2022117056A1 (zh) 2022-06-09
BR112023010891A2 (pt) 2023-10-17
AU2021391241A1 (en) 2023-07-20
AU2021391241B2 (en) 2024-05-09
JP2023552362A (ja) 2023-12-15
CN116615222A (zh) 2023-08-18
KR20230116894A (ko) 2023-08-04
US20240067702A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
EA202192099A2 (ru) Системы доставки с замедленным высвобождением, содержащие бесследные линкеры
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
EA202190650A1 (ru) Замедленная доставка ангиопоэтин-подобных полипептидов 3
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico
CO2020016480A2 (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
ECSP22050840A (es) Nuevos compuestos farmac?uticos
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")